TACSTD2 and cancer: Among the most recent breakthroughs in ADC technology, deruxtecan (DXd)-based ADCs have demonstrated exceptional efficacy in multiple cancer types, particularly those expressing human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and trophoblast cell surface antigen 2 (TROP2) [3,4,5].